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Abstract: Purpose: We evaluated the safety and effectiveness of the minimally invasive Superion
® Interspinous Spacer 
(VertiFlex, Inc., San Clemente, CA) in patients with moderate LSS. 
Methods: This single-arm prospective study enrolled 121 patients with moderate LSS between February 2008 and August 
2009 and were followed up at 1 (n=111), 3 (n=96), 6 (n=81), and 12 (n=52) months. All patients were treated with the 
Superion Interspinous Spacer. Main outcomes were back function with the Oswestry Disability Index (ODI), extremity 
and axial pain severity with an 11-point scale, health-related quality of life with the Physical Component Summary (PCS) 
and Mental Component Summary (MCS) scores from the SF-36, and adverse events through 12 months. 
Results: ODI improved 64% (p<0.001) through 12 months and clinical success was 92%. Extremity and axial pain 
improved 53% and 49% (both p<0.001), respectively, through 12 months with clinical success of 76% for axial pain and 
86% for extremity pain. Health-related quality of life improved 41% for PCS and 22% for MCS (both p<0.001) through 
12 months. PCS clinical success was 81% and MCS clinical success was 62% at 12 months. Four (5.9%) explants were 
performed although 3 were unrelated to the device. Eight procedure-related adverse events, observed in 6 (5.0%) patients, 
included superficial incision seroma (n=5), minor wound pain (n=2), and infection (n=1). 
Conclusions: Preliminary results with the Superion Interspinous Spacer suggest that it is an effective and safe treatment 
option for patients with moderate LSS who are unresponsive to conservative care. 
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INTRODUCTION 
  Lumbar spinal stenosis is characterized by narrowing of 
the lumbar spinal canal and/or the intervertebral foramina 
resulting from disc degeneration, bulging of the annulus, 
facet joint hypertrophy, and/or thickening of the ligamentum 
flavum [1-3], ultimately leading to compression of the neural 
and vascular elements in the lumbar spine [4]. Neurogenic 
claudication symptoms such as leg pain and/or weakness 
during walking result in lower quality of life and impaired 
functional capacity [5]. With the aging of the population and 
continuing advances in diagnostic imaging capabilities, 
lumbar spinal stenosis is becoming more frequently 
diagnosed with an estimated prevalence of 2 to 13% [6, 7]. 
  Nonsurgical management such as activity modification, 
pain-relieving and anti-inflammatory medications, physical 
therapy, and spinal injections are the first-line treatments for 
patients with mild symptoms although long-term success is 
marginal, partly because these therapies have no impact on 
disease progression [8-10]. Consequently, patients are often 
confronted with the dilemma of living with persistent pain 
and functional impairment or undergoing invasive surgery, 
most commonly laminectomy with or without fusion [11- 
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13], a procedure associated with substantial cost and 
morbidity [14-17]. However, there is no clear treatment 
algorithm for patients with moderate lumbar spinal stenosis 
who may obtain only partial relief from conservative 
measures, but where the severity of symptoms may not 
justify undergoing invasive surgery such as laminectomy. 
  Minimally invasive lumbar procedures have become 
increasingly popular over the past two decades [18] and 
represent a viable alternative that addresses this therapeutic 
gap. In particular, interspinous process decompression is a 
novel procedure that limits back extension at the 
symptomatic level by implantation of a spacer between 
contiguous spinous processes. This implant offers the 
potential to minimize neural injury risk versus alternative 
procedures and to preserve anatomical structures, thereby 
affording the option of more invasive surgery in the future 
should severe symptoms recur. Mid-term results suggest that 
interspinous spacers improve patient symptoms [19, 20], 
although long-term safety and effectiveness are currently 
unknown [21]. The purpose of this study was to evaluate 12-
month clinical outcomes in patients with lumbar spinous 
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MATERIALS AND METHODS 
Patients 
  This single-arm prospective study enrolled 121 patients 
with lumbar spinal stenosis from Asklepios Krankenhaus 
(Seligenstadt, Germany) between February 2008 and August 
2009. All patients were treated with the Superion
® 
Interspinous Spacer (VertiFlex, Inc.,  San Clemente, CA). 
Inclusion criteria for this study included (a) diagnosis of 
moderate lumbar spinal stenosis, defined as 25% to 50% 
reduction in lateral/central foramen diameter compared to 
adjacent levels and radiographic evidence of thecal sac 
and/or cauda equine compression, nerve root impingement 
by either osseous or non-osseous elements, and/or 
hypertrophic facets with canal encroachment, (b) persistent 
leg, buttock, or groin pain, with or without back pain, that 
was relieved by lumbar flexion, and (c) unsuccessful 
conservative treatment for at least 3 months. Exclusion 
criteria included (a) axial back pain only, (b) grade II to V 
spondylolisthesis, (c) unremitting back pain in any spinal 
position, (d) active systemic disease that may affect the 
welfare of the patient, (e) vertebral osteoporosis or history of 
vertebral fracture, and (f) pregnant or lactating female. The 
procedures used in this clinical study were in accordance 
with the recommendations of the Helsinki Declaration and 
each patient gave written, informed consent before surgery. 
Intervention 
  The Superion device is a single-piece titanium implant 
that is delivered percutaneously and deployed between the 
spinous processes of the symptomatic vertebral levels (Fig. 
1a, b). This novel interspinous spacer limits extension at the 
symptomatic level while preserving mobility, structural 
elements, and alignment. 
 
Fig. (1). Superion Interspinous Spacer in situ. (a) A/P view, (b) 
lateral view. 
  The minimally invasive procedure was undertaken with
the patient lying prone on a radiolucent table with the lumbar
spine in a neutral or slightly flexed position. Under 
fluoroscopic guidance or direct visualization, the surgical 
level was identified and a 12-15 mm midline incision was 
made. The supraspinous ligament was longitudinally 
dissected at the symptomatic level and then dilated to ensure 
adequate room to maneuver within the interspinous space. A 
cannula was inserted over the dilator and proper alignment 
and depth were ensured before dilator removal. Next, an 
interspinous gauge was inserted through the cannula to 
determine proper implant size selection and final midline 
positioning was confirmed under fluoroscopy. 
  The appropriately sized spacer was delivered through the 
cannula using a device inserter that loaded, inserted into the 
interspinous space via the cannula, and deployed the implant. 
Proper device placement was confirmed with fluoroscopy. 
Finally, the inserter and cannula were removed and the 
incision was sutured in a standard fashion. Proper placement 
of the implant is illustrated radiographically in Fig. (2). 
 
Fig. (2). (a) A/P and (b) lateral radiographic image showing a 
properly placed Superion Interspinous Spacer. 
Outcomes 
  Patients were assessed pre-treatment and then returned 
for follow-up visits at 1, 3, 6, and 12 months post-treatment. 
Degree of back-specific functional disability was measured 
with the Oswestry Disability Index (ODI) (version 2) on a 0 
to 100% scale [22]. Extremity and axial pain severity was Superion for Lumbar Stenosis  The Open Orthopaedics Journal, 2011, Volume 5    363 
measured with an 11-point numeric pain scale (0 to 10). 
Health-related quality of life was assessed with the SF-36 
(version 2) and Physical Component Summary (PCS) and 
Mental Component Summary (MCS) scores were recorded 
[23]. Safety was assessed by incidence of reported adverse 
events (AEs) through the 12-month follow-up period. 
Device-related AEs were defined as implant dislodgement, 
migration, fracture, or deformation that resulted in clinical 
sequelae or revision or explant for any reason. 
Data Analysis 
  Data were analyzed using Predictive Analytics Software 
(v. 18, SPSS, Inc., Chicago, IL). Continuous data were 
reported as mean ± SD and categorical data were reported as 
frequencies and percentages. Longitudinal changes in 
clinical outcomes were assessed with repeated measures 
analysis of variance. The revision rate over the 12-month 
follow-up period was estimated with Kaplan-Meier methods. 
Clinical success was defined as a 30% improvement in ODI 
[24, 25], 30% improvement in pain scores [24, 26], 5.7-
point improvement in PCS [27], and 6.3-point improvement 
in MCS [27], respectively. 
RESULTS 
  The typical patient was aged in the upper 50s, 
overweight-to-obese, presented with single level disease 
(most commonly at L4-L5), and suffered moderate-to-severe 
back and/or extremity pain and functional disability at 
baseline. Twenty-two (18%) patients presented with 
concomitant grade I spondylolisthesis. Mean procedure time 
was 1 hour and hospital stay averaged 3 days. Implant size 
ranged from 8 to 16 mm with the 12 and 14 mm devices 
accounting for 80% of implants (Table 1). At the time of this 
analysis, 52 patients had passed the 12-month follow-up visit 
window. ODI and pain data were available for 50 of 52 
(96%) patients and SF-36 data were available for all patients 
(52 of 52). 
Table 1.  Patient Baseline Characteristics 
 
Characteristic Value 
   (n=121) 
Age, mean ± SD, y   57.9 ± 13.5 
Female*, n (%)   60 (52.2) 
Body Mass Index
†, mean ± SD, kg/m
2  29.8 ± 5.0 
Treated Level, n (%)     
 L2  —  L3   4  (3.3) 
 L3  —  L4   12 (9.9) 
 L4  —  L5   105 (86.8) 
Procedure Duration
‡, mean ± SD, h  1.0 ± 0.2 
Length of Hospital Stay
§, mean ± SD, d  3.4 ± 1.1 
Axial Pain Severity Score
||, mean ± SD  6.9 ± 1.1 
Extremity Pain Severity Score
||, mean ± SD  6.6 ± 1.4 





||, 11-pt. numeric scale. 
 
Back-Specific Functional Impairment 
  Rapid improvements in ODI were noted in the first 
month following treatment (60±8% at pre-treatment to 
34±10% at 1 month). Between months 1 and 12, continued 
improvements in back function were noted with a 12-month 
mean value of 21±14%, representing a 64% (p<0.001) 
improvement from pre-treatment levels (Fig. 3). ODI clinical 
success at 12 months was 92% (46 of 50) (Fig. 4). 
 
Fig. (3). Improvement in back function through 12 months post-
treatment. 
 
Fig. (4). Back function clinical success rates through 12 months 
post-treatment. 
Extremity and Axial Pain Severity 
  Extremity pain decreased from 6.6±1.4 at pre-treatment 
to 3.3±1.4 at 1 month and 2.8±1.5 at 12 months, reflecting a 
53% overall improvement (p<0.001) (Fig. 5). Extremity pain 
clinical success at 12 months post-treatment was 86% (43 of 
50) (Fig. 6 ). Similar improvements were realized in axial 
pain with values of 6.9±1.1 at pre-treatment, 3.9±1.2 at 1 
month, and 3.4±1.5 at 12 months, which represented a 49% 
improvement compared to pre-treatment values (p<0.001) 
(Fig. 5). At 12 months post-treatment, 76% (38 of 50) of 
patients achieved axial pain clinical success (Fig. 6). 364    The Open Orthopaedics Journal, 2011, Volume 5  Bini et al. 
 
Fig. (5). Improvement in pain severity through 12 months post-
treatment. 
 
Fig. (6). Pain severity clinical success rates through 12 months 
post-treatment. 
Health-related Quality of Life 
  Six of eight SF-36 domains (PF, RP, RE, SF, BP, VT) 
improved as early as 1 month post-treatment with all 
domains showing a significant (all p<0.001) improvement 
through 12 months post-treatment (Fig. 7 ). Similar to the 
trends observed with ODI and axial and extremity pain 
scores, PCS and MCS each significantly improved from pre-
treatment to 1 month with continued improvements observed 
through the 12-month follow-up visit (p<0.001) (Fig. 8 ). 
Through 12 months, MCS clinical success was achieved in 
62% (32 of 52) of patients while PCS clinical success, 
arguably a more clinically important and relevant measure, 
was achieved in 81% (42 of 52) of patients (Fig. 9). 
Adverse Events 
  A total of 205 AEs were reported in 121 patients (1.7 per 
patient) through the 12-month follow-up period. Most AEs 
were of minor clinical importance and were unrelated to the 
procedure or the Superion device. Eight procedure-related 
AEs (5 wound complications, 2 reports of pain, and 1 
infection requiring explant on post-treatment day (PTD) 10) 
were reported in 6 (5.0%) patients. Four patients (5.9%) 
underwent device explant during the 12-month follow-up 
period including: (a) an infection-related revision on PTD 
10, (b) explant at 2 months due to bulging disk at L3-L4, (c) 
explant at 8 months due to osteochondrosis, and (d) explant 
at 11 months due to persistent pain. Postoperative 
radiographic review noted an incidental case of a slightly 
angled, albeit correctly placed, Superion device. The patient 
reported no clinical symptoms and received no treatment 
associated with this finding.  
 
Fig. (7). SF-36 assessment of quality of life through 12 months 
post-treatment. 
 
Fig. (8). Physical Component Summary and Mental Component 
Summary score improvement through 12 months post-treatment. Superion for Lumbar Stenosis  The Open Orthopaedics Journal, 2011, Volume 5    365 
 
Fig. (9). Physical Component Summary and Mental Component 
Summary success rates through 12 months post-treatment. 
DISCUSSION 
  The minimally invasive Superion Interspinous Spacer is a 
novel, low profile device that results in excellent safety and 
effectiveness based on the 12-month outcomes reported in 
the current study including improvements of 64% in ODI, 
53% for extremity pain, 49% for axial pain, 41% for PCS, 
and 22% for MCS. This study represents the first clinical 
account of patient outcomes with the Superion device. 
  Patient outcomes following treatment with the Superion 
device are comparable to those reported with laminectomy, 
which is the standard of care for surgical LSS treatment. 
Thomé and colleagues [28] treated 40 patients who presented 
with symptomatic lumbar spinal stenosis with wide 
laminectomy. Through 12 to 18 months following 
laminectomy, pain decreased 45%, PCS improved 38% and 
MCS improved 24%. However, perioperative complications 
were reported in 23% of patients and 12% required fusion or 
adjacent level decompression. These data were corroborated 
by a meta-analysis that reported a 13% overall complication 
rate for laminectomy including 0.3% perioperative mortality, 
6% dural tear, 3% infection, and 3% deep vein thrombosis 
[13]. Furthermore, overall success rates with laminectomy 
are highly variable, ranging from 26% to 100% [3, 13, 29, 
30]. Despite similar mid-term patient outcomes, the safety 
profile of the Superion device suggests fewer potential risks 
compared to laminectomy. 
  The Superion device also yields similar, if not slightly 
better, outcomes as the X-STOP Interspinous Process 
Decompression System, which is the only FDA-approved 
interspinous spacer. We reported a 53% improvement in leg 
pain and a 64% decrease in ODI. For comparison, a study of 
175 patients treated with the X-STOP device reported a 36% 
improvement in leg pain and a 55% ODI improvement 
through 12 months [19]. Complication rates of 9-12% [31, 
32] and a 58% secondary decompression surgery rate within 
2 years of implant [33] have been reported with the X-STOP 
device. The follow-up period in the current study extends 
only through 12 months so no direct comparison of 
complication and revision rates can be made with certainty. 
However, the smaller profile of the Superion device in 
addition to the less invasive percutaneous delivery of the 
implant versus the open procedure required for the X-STOP 
device may yield patient safety advantages (Fig. 10a, b). 
 
Fig. (10). A/P (a) and lateral (b) radiographs comparing the profile 
of the X-STOP versus the Superion interspinous spacers. 
  The excellent safety profile of the Superion device for 
treatment of lumbar spinal stenosis is likely because, unlike 
laminectomy, implant of this interspinous spacer avoids 
resection of the posterior spinal elements and thus does not 
compromise spinal stability and affords a reversible 
percutaneous device explant if required in the future. A finite 
element model of a lumbar spine that underwent 
laminectomy revealed that removal of the posterior elements 
resulted in increased flexion-extension and axial rotation at 
the surgical site and the authors concluded that minimization 
of bone and ligament removal, such as with the Superion 
procedure, results in greater lumbar stability [34] and 
potentially lowers risk for fusion surgery. In fact, a cadaver 
study demonstrated that implantation of the Superion device 366    The Open Orthopaedics Journal, 2011, Volume 5  Bini et al. 
prevents supraphysiological motion at the symptomatic level 
and has no adverse impact on the local anatomy [35]. 
  Despite the minimally invasive procedure of interspinous 
spacer implantation, the average hospital stay in the current 
study was 3 days. However, this was mainly to support 
adequate reimbursement under local regulations and did not 
accurately reflect the convalescence required following the 
procedure. In fact, an ongoing randomized clinical trial with 
the Superion device clarifies that implantation should be on 
an outpatient basis in most cases given the minimally 
invasive nature of the procedure [36]. 
  The main limitation of this study was the lack of a 
concurrent control group. Thus, the degree of clinical 
improvement realized by patients may be biased by non-
specific study effects, such as placebo. Regardless, the 
magnitude of positive clinical outcomes implies a strong 
beneficial treatment effect of the Superion device. Also, 
variability in patient follow-up length precludes a definitive 
assessment of 12-month clinical outcomes. Additional 
studies of this device are warranted to determine long-term 
safety and effectiveness outcomes. 
CONCLUSION 
  The Superion Interspinous Spacer is a safe and effective 
treatment option for carefully selected patients with 
moderate LSS who are unresponsive to conservative care. 
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